Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
ICLR 
ICON PLC (ICLR)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/30/2025: ICLR (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
17 Analysts rated it
Well-followed company, solid analyst reports, reliable data for confident investing.
1 Year Target Price $175.2
1 Year Target Price $175.2
| 11 | Strong Buy |
| 0 | Buy |
| 6 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 0.7% | Avg. Invested days 40 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 06/30/2025 |
Key Highlights
Company Size Large-Cap Stock | Market Capitalization 11.49B USD | Price to earnings Ratio 15.75 | 1Y Target Price 175.2 |
Price to earnings Ratio 15.75 | 1Y Target Price 175.2 | ||
Volume (30-day avg) 17 | Beta 1.16 | 52 Weeks Range 125.10 - 347.72 | Updated Date 06/29/2025 |
52 Weeks Range 125.10 - 347.72 | Updated Date 06/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 9.18 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 9.26% | Operating Margin (TTM) 13.21% |
Management Effectiveness
Return on Assets (TTM) 4.41% | Return on Equity (TTM) 8.01% |
Valuation
Trailing PE 15.75 | Forward PE 10.66 | Enterprise Value 14522033405 | Price to Sales(TTM) 1.4 |
Enterprise Value 14522033405 | Price to Sales(TTM) 1.4 | ||
Enterprise Value to Revenue 1.77 | Enterprise Value to EBITDA 10.05 | Shares Outstanding 79483800 | Shares Floating 78323940 |
Shares Outstanding 79483800 | Shares Floating 78323940 | ||
Percent Insiders 0.63 | Percent Institutions 100.35 |
Analyst Ratings
Rating 4 | Target Price 175.2 | Buy - | Strong Buy 11 |
Buy - | Strong Buy 11 | ||
Hold 6 | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
ICON PLC
Company Overview
History and Background
ICON PLC was founded in 1990 in Dublin, Ireland. Initially focused on bioanalytical laboratory services, it has grown through organic expansion and acquisitions to become a global provider of outsourced drug and device development and commercialization services.
Core Business Areas
- Clinical Development Services: ICON offers a full suite of clinical development services, including clinical trial management, data management, biostatistics, medical writing, and regulatory affairs.
- Commercialisation & Outcomes: Provides services to support product launches, market access, and real-world evidence generation.
- Labs Services: ICON Central Laboratory provides comprehensive laboratory testing services to support clinical trials across all phases of drug development.
Leadership and Structure
ICON is led by a CEO and a senior management team responsible for overseeing its various business units and functions. The company has a global organizational structure with operations in North America, Europe, Asia-Pacific, and Latin America.
Top Products and Market Share
Key Offerings
- Clinical Trial Management: Comprehensive management of clinical trials from Phase I to Phase IV. While specific market share data is difficult to pinpoint, ICON is a major player in the CRO market, which is highly fragmented. Competitors include IQVIA, Labcorp, and PPD (Thermo Fisher Scientific). Revenue generated from this is the majority of ICON's revenue (Approximately 90%)
- Laboratory Services: Central laboratory services supporting clinical trials. Specific market share data is not readily available. Competitors include Labcorp and Quest Diagnostics. Revenue generated from this is aproximately 10%.
Market Dynamics
Industry Overview
The CRO industry is experiencing strong growth driven by increasing R&D spending by pharmaceutical and biotechnology companies, the growing complexity of clinical trials, and the desire to outsource non-core activities.
Positioning
ICON is a leading global CRO with a reputation for providing high-quality services and innovative solutions. Its competitive advantages include its global reach, broad service offerings, and experienced team.
Total Addressable Market (TAM)
The global CRO market is estimated to be around $70-80 billion and is expected to continue to grow. ICON is well-positioned to capture a significant share of this market.
Upturn SWOT Analysis
Strengths
- Global reach and presence
- Broad service offerings
- Experienced management team
- Strong reputation for quality
- Diversified client base
Weaknesses
- High dependence on pharmaceutical and biotechnology R&D spending
- Competitive market
- Potential for project delays and cost overruns
- Integration risks associated with acquisitions
Opportunities
- Growing demand for CRO services
- Increasing complexity of clinical trials
- Expansion into new geographic markets
- Adoption of new technologies
- Strategic acquisitions
Threats
- Economic downturns
- Changes in regulatory requirements
- Increased competition
- Pricing pressures
- Loss of key clients
Competitors and Market Share
Key Competitors
- IQV
- LH
- TMO
Competitive Landscape
ICON has strong capabilities in clinical trial management and a global reach. It competes with larger CROs like IQVIA based on service breadth and technological innovation. Smaller, niche CROs may offer specialized expertise in certain therapeutic areas or trial phases.
Major Acquisitions
PRA Health Sciences
- Year: 2021
- Acquisition Price (USD millions): 12000
- Strategic Rationale: Expanded ICON's service offerings and scale, particularly in data and technology-enabled solutions. Strengthened ICON's position in the global CRO market.
Growth Trajectory and Initiatives
Historical Growth: Discuss ICON PLC's growth trends over the past years based on SEC filings. [Numerical data from recent financial statements]
Future Projections: Provide projections for ICON PLC's future growth based on analyst estimates from reputable sources like Yahoo Finance or Bloomberg. [Numerical data from recent financial statements]
Recent Initiatives: Highlight recent strategic initiatives undertaken by ICON PLC, such as acquisitions, partnerships, or new service offerings.
Summary
ICON PLC is a leading global CRO positioned for growth in a growing market. The acquisition of PRA Health Sciences significantly enhances its service offerings and market position. While competition remains intense, ICON's size, scope, and expertise provide a solid foundation. Monitoring global economic conditions and regulatory changes remains crucial.
Peer Comparison
Sources and Disclaimers
Data Sources:
- SEC Filings (10-K, 10-Q), Company Website, Press Releases, Industry Reports (e.g., from Gartner, Forrester), Yahoo Finance, Bloomberg
Disclaimers:
The information provided is for informational purposes only and should not be considered financial advice. Market data and analysis are based on available information and may be subject to change. Investment decisions should be based on thorough research and consultation with a qualified financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About ICON PLC
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 1998-05-15 | CEO & Director Dr. Steven A. Cutler MBA, Ph.D. | ||
Sector Healthcare | Industry Diagnostics & Research | Full time employees 41250 | Website https://www.iconplc.com |
Full time employees 41250 | Website https://www.iconplc.com | ||
ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies. It also provides clinical development services, including all phases of development, peri and post approval, data solutions, and site and patient access services; clinical trial management, consulting, and contract staffing services; and commercial services comprising clinical development strategy, planning and trial design, full study execution, and post-market commercialization. In addition, the company offers laboratory services, including bionanalytical, biomarker, vaccine, good manufacturing practice, and central laboratory services, as well as full-service and functional service partnerships to customers. Further, the company provides adaptive trials, cardiac safety solutions, clinical and scientific operations, consulting and advisory, commercial positioning, decentralized and hybrid clinical trials, early clinical, laboratories, language services, medical imaging, real world intelligence, site and patient, and strategic solutions. It serves pharmaceutical, biotechnology, and medical device industries, as well as government and public health organizations. ICON Public Limited Company was incorporated in 1989 and is headquartered in Dublin, Ireland.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.